---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-017226"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-05-15T12:30:15+00:00"
generated_at: "2026-05-15T12:36:23.982752+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moleculin Q1: Cash $10.3M; MIRACLE trial 40% CRc; 45 subjects enrolled

## Summary
- Cash and equivalents $10.3M as of March 31, 2026; R&D expense $5.4M (up $2.0M YoY) on MIRACLE trial costs.
- MIRACLE Phase 2B/3 trial: first 45 subjects enrolled; blinded composite complete remission (CRc) rate of 40%.
- First interim unblinding expected June 2026; 90th subject recruitment targeted for Q3 2026.
- Completed Q1 2026 financings with ~$8.3M gross proceeds; runway extended into Q3 2026.
- Expect to start pancreatic cancer trial in 2H 2026; aiming for rolling NDA submission for R/R AML in 2028.

## SEC filing metadata
- accession: 0001437749-26-017226
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-05-15T12:30:15+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926017226/0001437749-26-017226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926017226/mbrx20260514_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-017226
- JSON: https://secwatch.observer/filing/0001437749-26-017226.json
- Plain text: https://secwatch.observer/filing/0001437749-26-017226.txt

## Key facts
- Earnings Releases
  Moleculin Biotech, Inc. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 15, 2026, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and recent operational highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774926017226/0001437749-26-017226-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.